New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 13, 2012
07:36 EDTNBYNovaBay provides outlook for FY13
Dr. Ron Najafi, chairman and CEO, said, "2012 was an exciting year for NovaBay. As a result of the hard work from our talented employees and partners, all three of our Aganocide programs, in ophthalmology, dermatology, and urology, are currently in Phase 2 clinical trials. Data is expected from all of these trials in 2013. We plan to use our recent $7M financing to accelerate and expand these clinical trials," Dr. Najafi continued. "For example, we anticipate that these funds will allow us to speed enrollment of patients with additional sites in our global Phase 2b study for adenoviral conjunctivitis. Additionally, we intend to use proceeds from this financing to conduct a Phase 2 study of NVC-422 in bacterial conjunctivitis. We believe that having one product to treat both bacterial and viral conjunctivitis will place NovaBay in a leading position in the market. NVC-422 has the potential to be the conjunctivitis prescription, without need for a test to determine if a patient has the bacterial or the viral form of the disease."
News For NBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
07:05 EDTNBYNovaBay signs Avenova distribution agreement with Cardinal Health
Subscribe for More Information
January 21, 2015
08:23 EDTNBYNovaBay to hold a conference call
Subscribe for More Information
January 20, 2015
07:06 EDTNBYNovaBay expanding sales force for Avenova
NovaBay Pharmaceuticals announced that it is expanding its sales force for its innovative eye care product Avenova from 15 sales representatives to 35 representatives. Ron Najafi, Ph.D., Chairman and CEO of NovaBay, commented, “We plan to further increase our sales force to more than 50 representatives by July, which will allow us to reach more of the estimated 30 million Americans who suffer from eyelid conditions. We estimate the market opportunity for Avenova at $500 million annually in the U.S. alone.”

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use